Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus with Standard of Care in Gallbladder Cancer
NCT05833815Phase 3Recruiting
- Sponsor
- Banaras Hindu University
- Start
- Nov 2022
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of everolimus in gallbladder cancer (2 arms), sponsored by Banaras Hindu University. Primary endpoint: Progression free survival at 12 months. Started Nov 2022; status: recruiting.
02
Drugs
everolimus
03
Conditions
gallbladder cancer
Beyond the preview
Go deeper on NCT05833815.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05833815.